澳大利亚生物技术协会
澳大利亚医疗技术公司名录

公司介绍

公司名称： Osprey Medical Inc.

主要联系人姓名：Mike McCormick

主要联系人职务：首席执行官

公司网址：www.ospreymed.com

公司地址：5600 Rowland Road, Suite 250, Minnetonka MN USA 55343

公司已上市

公司简介

Osprey Medical 的核心技术来自于墨尔本 Baker IDI 心脏和糖尿病研究所 David Kaye 博士所做的研究。Osprey 专注于保护慢性肾病患者不患由造影剂引发的肾病(CIN)，防止糖尿病患者因重度足部感染而引发的截肢，从而提高患者的生活质量。本公司的主要产品，AVERT™ Plus 系统，旨在限制用于常规冠状动脉和外周血管成像碘化 X 射线染料的注射量，从而保护肾脏免受造影剂肾病(CIN)的伤害。造影剂肾病的高危患者通常是已患有慢性肾病。造影剂是有毒害的并会减缓肾脏内的血液流动，这可能会引发患者重度的并发症。避免造影剂肾病高危患者发病可以缩短住院时间，提高患者的治疗效果，并最终拯救患者的生命。

AVERT Plus 系统为医生和医院在血管造影过程中，减少并监测造影剂的用量提供了一个简单的方法。AVERT Plus 系统包含一个一次性工具包，内含 AVERT 造影剂调节库和一个拥有造影剂监控技术的智能注射器。这种一次性部件可以连接到重复使用的 AVERT 控制和监测显示系统上。

Osprey Medical 的董事会和管理层由对医疗器械开发、审批、销售和营销以及合并收购方面极富经验的成功人士组成。Osprey Medical 的顾问团由世界顶尖的心脏和肾脏专家组成。

Osprey Medical 成立于 2005 年，总部设于美国明尼苏达州的明尼通卡。本公司在澳大利亚证券交易所上市，公司代号”OSP”。

关键技术或领先技术

- Osprey 的 AVERT Plus 系统来自于澳洲墨尔本 Baker IDI 心脏和糖尿病研究所的研究。
- AVERT Plus 限制常规心脏和腿部 X 射线血管成像染料的用量。使用过多的染料可能引发不可逆转、可致死的造影剂肾病。
- AVERT Plus 已获得 FDA 批准并已被美国多家医院采用。

- Osprey 还在开发一种肢体恢复系统，它能更精准，更主动的将抗生素送达到重度足部感染的糖尿病患者的患处从而避免患者进行截肢手术。

类别

设备类：心脏科

关键或领先技术的发展阶段
已经获得注册

合作机会
1. 投资：个人和机构投资者
2. 客户：在重要地理位置的医院和医疗中心，包括美国和澳大利亚

Directory of Australian medtech companies

COMPANY DETAILS

Company name: Osprey Medical Inc.

Key contact name: Mike McCormick

Job title of key contact: Chief Executive Officer

Company website address: www.ospreymed.com

Company address: 5600 Rowland Road, Suite 250, Minnetonka MN USA 55343

The company is Listed.

ABOUT THE COMPANY

Osprey Medical's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker IDI Heart and Diabetes Institute. Osprey is focused on improving patients' quality of life by protecting those with chronic kidney disease from contrast induced nephropathy (CIN) and preventing limb amputation in diabetic patients with advanced foot infections. The Company's primary product, the AVERT™ Plus System, is designed to limit the amount of iodinated X-ray dye

(contrast) injected during commonly performed coronary and peripheral angiographic imaging procedures, thus protecting kidneys from damage known as contrast induced nephropathy (CIN). Patients at high risk of CIN often have pre-existing chronic kidney disease. The dye is toxic and can reduce the blood flow in kidneys which can lead to serious patient complications. Prevention of CIN in high risk patients may lead to shorter hospital stays, improved patient outcomes, and may ultimately save patients' lives.

The AVERT Plus System provides a simple way for doctors and hospitals to reduce and monitor the amount of contrast dye delivered to the patient undergoing an angiographic imaging procedure. The system consists of single use disposable convenience kit that includes the AVERT contrast modulation reservoir and a smart syringe with contrast monitoring technology. The disposable components attach to the reusable AVERT control system and monitor display unit.

Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

Osprey Medical was incorporated in 2005 with operations based in Minnetonka, Minnesota USA. The Company is publically traded on the Australian Securities Exchange ("ASX") under the symbol "OSP".

KEY OR LEAD TECHNOLOGY

- Osprey's AVERT Plus System originated from research done at the Baker IDI Heart and Diabetes Institute in Melbourne, Australia
- AVERT Plus works to limit the amount of dye used during commonly performed X-ray imaging procedures of blood vessels in the heart or legs. Excess dye can cause Contrast Induced Nephropathy (CIN), which can be irreversible, and can result in death.
- AVERT Plus is FDA cleared and is currently used in multiple hospitals in the US.
- Osprey is also researching a Limb Recovery System which works to save the limbs of diabetic patients suffering from advanced foot infections by allowing the delivery of antibiotics in a more targeted and aggressive manner.

Category

Devices: Cardiology

Point of development of key or lead technology

Has achieved registration

OPPORTUNITIES SOUGHT

1. Investment: Retail and institutional Investors
2. Customers: Hospitals and medical centres in key geographies including the USA and Australia.